Request Trial
Andrew Zappia, a partner in Troutman Pepper Locke's Health Care + Life Sciences Intellectual Property group
24 November 2025FeaturesAmericasAndrew Zappia

Still Unsettling: The uncertain landscape for discretionary denial

The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AI is transforming top 100 innovators, shows index
23 January 2026   Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.
Americas
Novartis win blocks generics relitigating $7.8bn heart drug patent
22 January 2026   A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
Americas
Leading the arena: WIPR identifies the top US trade secrets specialists of 2025
22 January 2026   New rankings from LSIPR’s sister title spotlight the firms and lawyers that are most successfully navigating the volatile world of trade secrets, from ‘prompt injections’ to billion-dollar retrials.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

AI is transforming top 100 innovators, shows index
Novartis win blocks generics relitigating $7.8bn heart drug patent
Leading the arena: WIPR identifies the top US trade secrets specialists of 2025
Rooted rights: Lessons from plant patent infringement and invalidity cases
Cadwalader global head among trio moving to Orrick
Skinny labels, big stakes: SCOTUS lines up the case of the year
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman